Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Cross-Neutralizing Activity Against SARS-CoV-2 Variants in COVID-19 Patients: Comparison of 4 Waves of the Pandemic in Japan

18 Aug 2021

Abstract excerpt

BACKGROUND: As of March 2021, Japan is facing a fourth wave of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection. To prevent further spread of infection, sera cross-neutralizing activity of patients previously infected with conventional SARS-CoV-2 against novel variants is important but has not been firmly established. METHODS: We investigated the neutralizing potency of 81 coronavirus...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to COVID-19 Clinical Research Studies
Share to Long-Term Effects of COVID-19
Share to SARS-CoV-2 and COVID-19 Research

Methodology Data sources Editorial policy Privacy Delete account & data About Contact Helena Bioinformatics

Source

Identifiers

PMID: 34631915
DOI: 10.1093/ofid/ofab430

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 9 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Cross-Neutralizing Activity Against SARS-CoV-2 Variants in COVID-19 Patients: Comparison of 4 Waves of the Pandemic in JapanPMID 34631915Read ↗

Cross-neutralizing activity against SARS-CoV-2 variants in COVID-19 patients: Comparison of four waves of the pandemic in JapanSemantic proximity Read ↗

Serum Neutralizing Activity against B.1.1.7, B.1.351, and P.1 SARS-CoV-2 Variants of Concern in Hospitalized COVID-19 Patients.Semantic proximity Read ↗

Serum from COVID-19 patients early in the pandemic shows limited evidence of cross-neutralization against variants of concernSemantic proximity Read ↗

Antibody Responses Against Coronaviruses in the Wuhan PopulationSemantic proximity Read ↗

Neutralizing antibody activity in convalescent sera from infection in humans with SARS-CoV-2 and variants of concern.Semantic proximity Read ↗

Humoral immune response of patients infected by earlier lineages of SARS-CoV-2 neutralizes wild types of the most prevalent variants in BrazilSemantic proximity Read ↗

SARS-CoV-2 cross-reactive B-cells outnumber seasonal coronavirus spike-specific clones at the end of the COVID-19 pandemicSemantic proximity Read ↗

SARS-CoV-2 501Y.V2 (B.1.351) elicits cross-reactive neutralizing antibodiesSemantic proximity Read ↗

Broad cross-neutralizing antibodies against animal-associated sarbecoviruses generated by SARS-CoV-2 infection and vaccination in humansSemantic proximity Read ↗

Comparable neutralization of SARS-CoV-2 Delta AY.1 and Delta in individuals sera vaccinated with BBV152Semantic proximity Read ↗

SARS-CoV-2 variants of concern exhibit reduced sensitivity to live-virus neutralization in sera from CoronaVac vaccinees and naturally infected COVID-19 patientsSemantic proximity Read ↗

Isolation and Characterization of Cross-Neutralizing Coronavirus Antibodies from COVID-19+ SubjectsSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.